Please login to the form below

Not currently logged in
Email:
Password:

elosulfase alfa

This page shows the latest elosulfase alfa news and features for those working in and with pharma, biotech and healthcare.

BioMarin's real world data sways NICE on orphan drug Vimizim

BioMarin's real world data sways NICE on orphan drug Vimizim

Rare genetic disorder treatment recommended in final draft guidance. NICE has issued final draft guidance recommending BioMarin Pharma's Vimizim (elosulfase alfa) for the treatment of the rare genetic disorder Morquio ... disease, and that health and

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Sales of the product will fit well into BioMarin's commercial infrastructure for its enzyme replacement therapies Naglazyme (galsulfase), for the treatment of Mucopolysaccharidosis VI, and Vimizim (elosulfase alfa) for Morquio

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics